custom feedback posit propos acquisit
custom feedback relat propos acquisit cover posit
appear valid strateg rational acquisit friday solicit feedback research sever top
genom center unit state given rapid innov special natur genom research ere keen
hear custom thought pacbio latest updat sequel platform also believ custom recept
situat import given tight-knit industri ould consid concern issu hich ere
concern believ posit custom respons confirm strategi reiter overweight rate
observ
research believ propos combin entiti would offer addit valu two compani could offer
separ custom understood strateg rational one question merit transact one research
note innov pacbio technolog ould good thing industri thought propos
acquisit good invest part anoth custom note ith long short read potenti offer
singl vendor ould help custom improv convict streamlin leverag cost effici
collabor project custom clearli understand strateg rational acquir pacbio
interest pacbio latest product enhanc get fund place util technolog background
earli octob pacbio announc enhanc sequel platform ith new ell chip new softw upgrad
new consum reagent improv scalabl throughput platform one custom note us alreadi
ow tw pacbio sequel million dollar grant support use instrument futur research anoth custom
note center line pilot experi understand util long read supplement short read
sequenc improv human variant call propos increas scale new chip step right direct
tow ard build interest ith custom anoth custom note ow ned one sequel new chip could
improv price point could justifi research bacteri genom
final custom dont appear consid short read solut pacbio long-read offer direct
competitor support manag view look gain regulatori approv one custom note believ long
read alon limit market vs sizabl grow ing potenti short read combin long short read could
provid optim solut address human variat anoth custom ad long read help ith region
complex repetit area short read technolog less effect manag believ
regulatori barrier close acquisit compani compet differ market segment
point reason disagre view
addit thought thesi pleas see
complement grow th long read ith pacbio strateg
inc momentum continu horizon pt
proprietari novaseq survey say elast upgrad ow
pleas reach us ith question thank
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens ill
directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog price target repres adj ep forecast target multipl base
histor ratio earn grow th project high-teen forseeabl futur
risk may imped achiev barclay research valuat price given pace innov
cycl next gener sequenc believ incumb maintain high level innov extend
advantag versu peer addit long-read sequenc technolog could disrupt advantag short-read
sequenc final given nascent opportun clinic remain potenti greater competit risk
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc thomson reuter last avail close price relev trade market unless anoth time
sourc indic
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur
issuer previou month
 employe non-execut director barclay bank plc and/or affili director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic
issuer ithin next month
fa barclay bank plc and/or affili benefici ow ns class equiti secur issuer calcul
fb barclay bank plc and/or affili benefici ow ns long posit class equiti secur
issuer calcul accord ith eu regul
fc barclay bank plc and/or affili benefici ow ns short posit class equiti secur
issuer calcul accord ith eu regul
gd one analyst fundament credit coverag team member household financi interest
debt equiti secur issuer
ge one analyst fundament equiti coverag team member household financi interest
debt equiti secur issuer
 issuer benefici ow ns class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement ith issuer provis financi servic barclay
bank plc and/or affili
 barclay bank plc and/or affili liquid provid and/or trade regularli secur issuer and/or
 barclay bank plc and/or affili receiv non-invest bank relat compens includ compens
brokerag servic applic issuer ithin past month
 issuer past month invest bank client barclay bank plc and/or affili
issuer past month non-invest bank client secur relat servic barclay
bank plc and/or affili
 issuer past month non-invest bank client non-secur relat servic
barclay bank plc and/or affili
use
 partner director offic barclay capit canada inc preced month provid servic subject
compani remuner normal cours invest advisori trade execut servic
 barclay bank plc and/or affili corpor broker issuer
 barclay capit canada inc and/or affili receiv compens invest bank servic issuer
issuer corpor broker barclay plc
barclay bank plc and/or affili provid equiti advisori servic issuer
 equiti secur canadian issuer includ subordin vote restrict share
 equiti secur canadian issuer includ non-vot restrict share
guid barclay fundament equiti research rate system
coverag analyst use rel rate system hich rate stock overw eight equal eight underw eight see
definit rel compani cover analyst team analyst deem
industri industri coverag univers see list compani compris particular industri coverag univers pleas
go http //publicresearch barclay com
addit stock rate provid industri view hich rate outlook industri coverag univers posit
neutral neg see definit rate system use term buy hold sell equival rate
system investor care read entir research report includ definit rate infer content
rate alon
overweight stock expect outperform unw eight expect total return industri coverag univers
equal weight stock expect perform line ith unw eight expect total return industri coverag univers
invest horizon
underweight stock expect under-perform unw eight expect total return industri coverag univers
rate suspend rate target price suspend temporarili due market event made coverag
impractic compli ith applic regul and/or firm polici certain circumst includ invest
barclay plc act advisori capac merger strateg transact involv compani
posit industri coverag univers fundamentals/valu improv
neutral industri coverag univers fundamentals/valu steadi neither improv deterior
neg industri coverag univers fundamentals/valu deterior
distribut rate
barclay equiti research compani coverag
assign overw eight rate hich purpos mandatori regulatori disclosur classifi buy
